Study group consisted of 10 proliferative endometrium, 22 simple endometrial hyperplasia, 23 endometrial intraepithelial neoplasia (EIN) and 30 Grade 1 endometrioid adenocarcinoma patients. AM and Bcl-2 expressions were investigated by immunohistochemistry.
Mean AM Allred score was 3 ± 2.6, 5.6 ± 1.6 and 5.7 ± 2.5 in benign, EIN and adenocarcinoma groups, respectively. AM expression was significantly higher in EIN and adenocarcinoma groups than in benign endometrium group (p < 0.05). Mean Bcl-2 Allred score was 6.4 ± 2.1, 5.2 ± 2.6, 2.3 ± 2 in benign endometrium, EIN and adenocarcinoma groups, respectively. Mean Bcl-2 Allred score was similar between benign endometrium and EIN groups (p > 0.05). However, it was significantly lower in adenocarcinoma group (p < 0.05). An inverse correlation between AM and Bcl-2 expressions was found (r: −0.4, p < 0.001).
Our findings showed that AM expression increased in progression from benign endometrium to EIN and type-1 adenocarcinoma while expression of Bcl-2 decreased in transition from EIN to carcinoma.